UTR Therapeutics' UTRxMYCN M1-14 receives US FDA Orphan Drug Designation and Rare Pediatric Disease Designation

30 September 2026 - UTR Therapeutics Inc, a New York-based biotech company, announced on Tuesday that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to 3'UTRMYCN M1...